ArticleThorax2024
Type-2 inflammation and lung function decline in chronic airway disease in the general population.
Article in Thorax, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.The Lancet. Respiratory medicine · 2026Pooled it
- Pooled it
- Fractional exhaled nitric oxide at multiple flow rates in chronic cough: association with lung function and airway hyperresponsiveness.Annals of medicine · 2026Article
- Fractional exhaled nitric oxide and blood eosinophils in relation to lung function, allergy and nasal polyps in asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy.ERJ open research · 2026Article
- Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.Allergy · 2026Observational
- From mild-to-moderate to severe asthma: risk factors and patient profiles from the NORDSTAR cohort.American journal of respiratory and critical care medicine · 2026Observational
- Airway epithelial transcriptional response to daily high-dose inhaled corticosteroids in asthma.ERJ open research · 2026Article
- Role of oral bacteria composition and functional gene profiles in respiratory diseases.BMJ open respiratory research · 2026Article
- Protective Effect of ThaiFood science & nutrition · 2026Article
- Comparative effectiveness of biologics in lung function improvement among patients with severe asthma: a real-world study.Respiratory research · 2026Article
- Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation.Frontiers in immunology · 2026Review
- Severe COPD Exacerbators Requiring Multiple ICU Admissions Over Time: Insights of a French Cohort.International journal of chronic obstructive pulmonary disease · 2026Article
- Persistent Airflow Limitation in Asthma: Clinical Characteristics, Risk Factors, and Long-term Outcomes from a Multicenter Cohort Study.Journal of asthma and allergy · 2026Article
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Beyond Blood Eosinophils: Target-Tier Heterogeneity and Patient Enrichment in COPD Type 2 Inflammation.Journal of inflammation research · 2026Review
- Differences in Type 2 Phenotype and Clinical Characteristics of Adult Asthma Patients with Different Severity, Across GINA Step 1 to 5 Asthma.Journal of asthma and allergy · 2026Article
- Association of Blood Eosinophil Counts with Expiratory Airflow Limitation: A Multi-Ethnicity Observational Study.Journal of inflammation research · 2026Article
- Resident eosinophils in patients with chronic obstructive pulmonary disease: a pilot study.Frontiers in medicine · 2026Article
- Persistent and unstable eosinophil levels in the sputum and blood: impact on the clinical prognosis of patients with chronic obstructive pulmonary disease.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is unclear if type-2 inflammation is associated with accelerated lung function decline in individuals with asthma and chronic obstructive pulmonary disease (COPD). We tested the hypothesis that type-2 inflammation indicated by elevated blood eosinophils (BE) and fraction of exhaled nitric oxide (FeNO) is associated with accelerated lung function decline in the general population.
methodsWe included adults from the Copenhagen General Population Study with measurements of BE (N=15 605) and FeNO (N=2583) from a follow-up examination and assessed forced expiratory volume in 1 s (FEV
resultsFEV
conclusionsType-2 inflammation indicated by elevated BE and FeNO is associated with accelerated FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.